RECRUITINGOBSERVATIONAL
Open-Source Artificial Pancreas System Use Among People With Type 1 Diabetes Mellitus in China
The Safety and Efficacy of Open-Source Artificial Pancreas System Among People With Type 1 Diabetes Mellitus in China
About This Trial
This real-world observational study aims to reveal the current status of the open-source artificial pancreas system (APS) use among people with T1DM in China and assess the glycemic efficacy and potential related factors of the open-source APS.
Who May Be Eligible (Plain English)
Who May Qualify:
1. diagnosed T1DM.
2. Currently use open-source APS for at least 3 months.
3. Willing and able to provide willing to sign a consent form (or be a parent or other legally authorized representative) and to provide the data.
4. reside in China.
Who Should NOT Join This Trial:
None
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. diagnosed T1DM.
2. Currently use open-source APS for at least 3 months.
3. Willing and able to provide informed consent (or be a parent or other legally authorized representative) and to provide the data.
4. reside in China.
Exclusion Criteria:
None
Treatments Being Tested
DEVICE
open-source APS;
a continuous glucose monitoring system, an insulin pump, and an intelligent algorithm.
Locations (1)
Jinhua Yan
Guangzhou, Guangdong, China